Search results for "CD3"

showing 10 items of 420 documents

Poorly differentiated synovial sarcoma: A case report

2001

Poorly differentiated synovial sarcoma is a rare soft tissue tumor. We studied a case arising in the pleural cavity of a young subject, characterised by the presence of spindle cell, small cell, and large epithelioid cell areas. We performed stains for mucosubstances and analysed the expression of cytokeratins 5/6, 7, 8, 18, 19, CEA, CD34, Ber-Ep4 and calretinin to characterize the phenotype of this neoplasm. We furthermore assessed immunohistochemically the presence of p53, Bcl-2, Bax and caspase 3, four apoptotic markers, to evaluate a relationship between apoptotic activity and the behaviour of this tumor. Our findings showed a strong presence of calretinin, p53 and Bcl-2 in all three ar…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyPleural Neoplasms2734CD34Caspase 3Pathology and Forensic MedicineSynovial sarcomaImmunoenzyme TechniquesSarcoma SynovialS100 Calcium Binding Protein GBcl-2-associated X proteinCalretininProto-Oncogene ProteinsBiomarkers TumormedicineHumansCaspasebcl-2-Associated X ProteinbiologyCaspase 3ApoptosiSoft tissue tumorGeneral MedicinePoorly differentiated synovial sarcomamedicine.diseaseSynovial sarcomaNeoplasm ProteinsApoptosis; Calretinin; Poorly differentiated synovial sarcoma; Soft tissue tumors; Synovial sarcoma; Cancer Research; Oncology; 2734Proto-Oncogene Proteins c-bcl-2OncologyCalbindin 2Caspasesbiology.proteinSarcomaTumor Suppressor Protein p53CalretininEpithelioid cell
researchProduct

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

2005

BACKGROUND In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg®), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML). METHODS Patients with CD33-positive AML in first recurrence were entered in 3 open-label, single-arm, Phase II studies. Patients received monotherapy with GO 9 mg/m2 as a 2-hour intravenous infusion in 2 doses separated by 2 weeks. Patients were evaluated for remission, survival, and treatment-emergent adverse events. RESULTS Two hundred seventy-seven patients (median age, 61 yrs) were treated with GO, and 71 patients (26%) achieved remission, which was defined as ≤ 5% blasts in the bone marrow wit…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidMaximum Tolerated DoseGemtuzumab ozogamicinmedicine.medical_treatmentCD33Sialic Acid Binding Ig-like Lectin 3Antigens Differentiation MyelomonocyticHematopoietic stem cell transplantationNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleClinical Trials Phase II as TopicAntigens CDRecurrenceInternal medicinemedicineHumansSingle-Blind MethodSurvival rateAgedAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseGemtuzumabSurgerySurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureAminoglycosidesTreatment OutcomeOncologyEvaluation Studies as TopicFemalebusinessmedicine.drugFollow-Up StudiesCancer
researchProduct

CONSISTENT BONE MARROW-DERIVED CELL MOBILIZATION FOLLOWING REPEATED SHORT COURSES OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH AMYOTROPH…

2009

Background and aims. The aim of this study was to evaluate and characterize the feasibility and safety of bone marrow-derived cell (BMC) mobilization following repeated courses of granulocyte-colony stimulating factor (G-CSF) in patients with amyotrophic lateral sclerosis (ALS). Methods. Between January 2006 and March 2007, 26 ALS patients entered a multicenter trial that included four courses of BMC mobilization at 3-month intervals. In each course, G-CSF (5 mu g/kg b.i.d.) was administered for four consecutive days; 18% mannitol was also given. Mobilization was monitored by flow cytometry analysis of circulating CD34(+) cells and by in vitro colony assay for clonogenic progenitors. Co-exp…

AdultMaleCancer Researchmedicine.medical_specialtySLa - trial clinico - C-GSFImmunologyAntigens CD34Bone Marrow CellsDrug Administration ScheduleColony-Forming Units AssayCell MovementInternal medicineMulticenter trialmedicineImmunology and AllergyHumansCell LineageProspective StudiesAmyotrophic lateral sclerosisProspective cohort studyGenetics (clinical)Hematopoietic Stem Cell MobilizationNeuronsTransplantationMobilizationbusiness.industryStem CellsAmyotrophic Lateral SclerosisGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationCell BiologyMiddle Agedmedicine.diseaseHematopoietic Stem CellsBone Marrow-Derived CellHematopoietic Stem Cell MobilizationSurgeryGranulocyte colony-stimulating factorNerve RegenerationSettore MED/26 - NEUROLOGIAGranulocyte macrophage colony-stimulating factorTreatment OutcomeOncologyBiological MarkersFemalebusinessNeurogliaBiomarkersmedicine.drug
researchProduct

Modifications of general parameters of immune activation in the sera of Sicilian patients with Boutonneuse fever

1998

SUMMARYThe serum levels of β2-microglobulin (β2-M), soluble HLA class I antigen (sHLA-I), soluble CD4 (sCD4) and CD8 (sCD8) were studied in 98 Sicilian patients with Boutonneuse fever (BF). In different stages of infection all markers were significantly increased in sera from Sicilian patients with acute BF compared with healthy controls. sCD8 and sHLA-I reached the peak in the second week after the onset of symptoms, whereas sCD4 and β2-M reached the peak in the first week. Afterwards sCD8 decreased to the levels of controls within the third week, the other parameters decreased later and were unmodified until the third week of infection. Significant correlations were found between sCD4 and…

AdultMaleCellular immunityCD8 AntigensCD3ImmunologyBoutonneuse FeverImmune systemT-Lymphocyte SubsetsmedicineHumansImmunology and AllergyAgedbiologyBeta-2 microglobulinHistocompatibility Antigens Class IMiddle Agedmedicine.diseasebiology.organism_classificationBoutonneuse feverRickettsiaSolubilityCD4 AntigensImmunologybiology.proteinFemaleOriginal Articlebeta 2-MicroglobulinRickettsia conoriiCD8Clinical and Experimental Immunology
researchProduct

Successful treatment of resistant thrombotic thrombocytopenic purpura/hemolytic uremic syndrome with autologous peripheral blood stem and progenitor …

1999

The first-line treatment of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS syndrome) induces a response and survival rate of approximately 85%, even if a considerable number of patients relapse; nevertheless, a number of these patients are resistant to conventional management. Immunoablation followed by stem cell transplantation has been shown to be capable of inducing remissions in a large spectrum of experimental autoimmune disorders. We report here the case of a 20-year-old male patient with the TTP-HUS syndrome who was resistant to conventional treatment and was transplanted with autologous immunoselected CD34+ PBPC after conditioning with cyclosphosphamide, anti…

AdultMaleHemolytic anemiaLymphocyteThrombotic thrombocytopenic purpuraAntigens CD34Transplantation AutologousPrednisonehemic and lymphatic diseasesHumansMedicineProgenitor cellSurvival rateTransplantationPurpura Thrombotic Thrombocytopenicbusiness.industryHematopoietic Stem Cell TransplantationHematologyHematopoietic Stem Cellsmedicine.diseaseTransplantationmedicine.anatomical_structureHemolytic-Uremic SyndromeImmunologyStem cellbusinessmedicine.drugBone Marrow Transplantation
researchProduct

A novel B cell population revealed by a CD38/CD24 gating strategy: CD38−CD24− B cells in centenarian offspring and elderly people

2012

The B cell arm of adaptive immunity undergoes significant modifications with age. Elderly people are characterized by impaired B cell responses reflected in a reduced ability to effectively respond against viruses and bacteria. Alterations of immunity with advancing age (immunosenescence) have been widely studied in centenarians who are considered a good example of successful aging. In recent years, attention has shifted to centenarian offspring (CO) as a model of people genetically advantaged for healthy aging and longevity. Here, we describe the preliminary characterization of a proposed new population of memory B cells, defined as CD19(+)CD38(-)CD24(-), which we find at higher frequencie…

AdultMaleParentsAgingCD180OffspringImmunosenescencePopulationB cell; CD38; CD24; CD180; Immunosenescence; Centenarian offspringLongevityCentenarian offspringCD38Lymphocyte ActivationCD19Article03 medical and health sciences0302 clinical medicineReference ValuesmedicineHumanseducationCD24B cell030304 developmental biologyAgedSettore MED/04 - Patologia GeneraleAged 80 and over0303 health scienceseducation.field_of_studyB cellB-LymphocytesImmunity CellularbiologyCD24 AntigenGeneral MedicineImmunosenescenceMiddle AgedAcquired immune systemADP-ribosyl Cyclase 13. Good healthmedicine.anatomical_structureImmunologybiology.proteinCytokinesFemaleGeriatrics and GerontologyCentenarianCD38030215 immunology
researchProduct

Immunohistochemical study of Langerhans cells in periapical lesions: correlation with inflammatory cell infiltration and epithelial cell proliferatio…

2008

Aim: The aim of this study is to determine the presence and distribution of Langerhans cells in periapical lesions, and correlate this with inflammatory cell infiltration and epithelial cell proliferation. Material and Methods: Seventy chronic dental periradicular lesions, obtained during periapical surgery from 70 patients, were included in this study, including: 46 granulomas, 18 scar tissue and 6 periradicular cysts. Immunohistochemical staining was performed using the following markers: CD3 to analyze the inflammatory infiltrate, CD1a to determine the presence of Langerhans cells and Ki67 to analyze the epithelial cell proliferation. The CD1a immunostaining density was established follo…

AdultMalePathologymedicine.medical_specialtyAdolescentCD3StainYoung AdultmedicineHumansGeneral DentistryCell Proliferationbiologybusiness.industryPeriapical DiseasesEpithelial CellsMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseImmunohistochemistryEpitheliumStainingPeriradicularmedicine.anatomical_structureOtorhinolaryngologyLangerhans CellsUNESCO::CIENCIAS MÉDICASbiology.proteinImmunohistochemistrySurgeryFemalebusinessInfiltration (medical)ImmunostainingMedicina oral, patologia oral y cirugia bucal
researchProduct

Primordial odontogenic tumor : a systematic review

2019

Background The primordial odontogenic tumor (POT) is a recently described benign entity with histopathological and immunohistochemical features suggesting its origin during early odontogenesis. Aim: To integrate the available data published on POT into a comprehensive analysis to better define its clinicopathological and molecular features. Material and Methods An electronic systematic review was performed up to September 2019 in multiple databases. Results A total of 13 publications were included, representing 16 reported cases and 3 molecular studies. The mean age of the affected patients was 11.6 years (range 2-19), with a slight predominance in males (56.25%). The posterior mandible was…

AdultMalePathologymedicine.medical_specialtyAdolescentCD34VimentinOdontogenic TumorsMandibleReviewEpitheliumLesionVariable Expression03 medical and health sciencesYoung Adult0302 clinical medicineSurvivinmedicineHumansPrimordial odontogenic tumorChildGeneral DentistryOral Medicine and Pathologybiologybusiness.industryOdontogenic tumor030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseasestomatognathic diseasesOtorhinolaryngologyChild PreschoolUNESCO::CIENCIAS MÉDICASbiology.proteinSystematic reviewImmunohistochemistryOdontogenesisSurgerymedicine.symptomAmelogeninNeoplasm Recurrence Localbusiness
researchProduct

Detection of residual leukemic blasts in adult patients with acute T-lymphoblastic leukemia using bone marrow trephine biopsies: comparison of fluore…

2010

Evaluation of remission in adult acute lymphoblastic leukemia (ALL) normally relies on cytologic evaluation and flow-cytometric analysis. The diagnostic impact of bone marrow trephine biopsies has not been studied so far. We investigated 26 biopsies of 16 patients with T-ALL. Double fluorescent immunostaining with TdT and CD3 was performed. Corresponding cytologic evaluation and flow-cytometric data were available. In 17 of 26 investigations, the results were concordant (either positive or negative). In one examination, residual blasts were not recognized by trephine biopsy, but by other methods. By contrast, in eight investigations, the leukemic blasts were found only in the bone marrow tr…

AdultMalePathologymedicine.medical_specialtyCD3BiopsyCytological TechniquesFluorescent Antibody TechniqueCell SeparationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaSensitivity and SpecificityPathology and Forensic MedicineFlow cytometryYoung AdultBone MarrowCytologyBiopsyMedicineHumansmedicine.diagnostic_testbiologybusiness.industryCell BiologyMiddle AgedFlow CytometryMinimal residual diseaseAdult Acute Lymphoblastic Leukemiabiology.proteinImmunohistochemistryFemalebusinessImmunostainingPathology, research and practice
researchProduct

Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients

2015

Melanomas are aggressive skin tumors characterized by high metastatic potential. Our previous results indicate that Natural Killer (NK) cells may control growth of melanoma. The main defect of blood NK cells was a decreased expression of activating NCR1/NKp46 receptor and a positive correlation of NKp46 expression with disease outcome in stage IV melanoma patients was found. In addition, in stage III melanoma patients, we identified a new subset of mature NK cells in macro-metastatic Lymph nodes (LN). In the present studies, we evaluated the numbers of NK cells infiltrating primary cutaneous melanoma and analyzed immune cell subsets in a series of sentinel lymph nodes (SLN). First, we show …

AdultMalePathologymedicine.medical_specialtyCD34lcsh:MedicineCD8-Positive T-LymphocytesBiologyTumor MicroenvironmentmedicineHumansCytotoxic T celllcsh:ScienceMelanomaAgedNeoplasm StagingAged 80 and overTumor microenvironmentMultidisciplinarySentinel Lymph Node BiopsyMacrophagesMelanomalcsh:REndothelial CellsMiddle Agedmedicine.diseaseAntigens Differentiation3. Good healthKiller Cells NaturalGranzyme BCutaneous melanomalcsh:QFemaleLymphCD8Research ArticlePLOS ONE
researchProduct